{"name":"Tisento Therapeutics","slug":"tisento-therapeutics","ticker":"","exchange":"","domain":"tisento.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQbjhjTHczOV9nbUlmODIzMk9qNW9MQnJ4UXVhYXdNdkgwU2wya1ZPTnVjSlEtMzFqbGVjbFc5Z25Lemw4UDdkYXBSRlZQckQ4OGg0Xy0td0hnZndtUTJRWUhWOG5aNjYwLVdPR21KU2JHMHFVbHVDSDlYeGlObWR6QkJaM0RTaHBXRHBUaEJWbWFLQ2c?oc=5","date":"2026-04-01","type":"deal","source":"The Business Journals","summary":"Cyclerion provides public listing vehicle for Korsana in $380M deal - The Business Journals","headline":"Cyclerion provides public listing vehicle for Korsana in $380M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOdC1ZWUdxSWRVUFFvOVkwbFd4Q2JsWWZ1XzZvZU5CLVZZVEMzWEp5RHBBNTZRTkg5TU5YMUp1LUFmQUJLSmJGVmw3dFBtMFdZTi1pbllBMjRiQkFYR1ZjSER5Z0Zsa3lBWEFuTkgxX2o5ZjMteG51SEZXZU1vRXdyZXdLcVJOMHVfWW1mQmFMTlQ0UVNnTWN6ZmVZQ1dIUHByZk5TV2dDSU5IU1U5Y1p3dFpyYw?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Cyclerion (NASDAQ: CYCN) doubles down on TRD program as cash runway tightens - Stock Titan","headline":"Cyclerion (NASDAQ: CYCN) doubles down on TRD program as cash runway tightens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB3My1wU3dZY1d4b2g2N0VPYUM1ckJ3aGs5OFo5dXd5SFhRTEZUUFY4Vndfd1VkUFZEYXR3MWI2WFg1ejNnVHJkSHhnRFdURlBFYmkwTUJYLXRvM1k4djV2Ym8wMnNuZ0VTRzA2Z3p3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Cyclerion Therapeutics Inc (CYCN) - Stock Titan","headline":"If You Invested $1,000 in Cyclerion Therapeutics Inc (CYCN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPN0NCX291VlZQTnBpSi16TlZpYldGeWlydWh1QkY1N3RMc194QnRnQTFCZlFMMTloZ2RnR1NBWEZEdmQzc0pPQTlfRDFkUkJFVjViSG0za1ZKTGJqYlRaUURIRlZpM0hZRDBDNDRaaXFSOXdvWG9XZHc1Y3pPT3AwbHJEN3AtZjlnNVFET3hBalV6TFBXTUNPWGJuOEhkMlk5SDhwZFFQaWV4NXBsZVdZRUxVWEJoSHJuYmN1LXBJQVVpRWtrcVc4dS1ldVdsbzJOOXZHS2t1ejVhQnRFNzBtTFBmT0tnZi1kUmI1dTdsTEhvQlQxQjdoN3luNUxPdk4wZU90elU3Yy1UTmhucWxxRzlid2Radw?oc=5","date":"2026-01-08","type":"pipeline","source":"GlobeNewswire","summary":"Tisento Therapeutics Completes Enrollment in PRIZM, a - GlobeNewswire","headline":"Tisento Therapeutics Completes Enrollment in PRIZM, a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9RRW1FZ2VrdE1lM2NLbThnUk5EX3RFaVd3aGdlRzBBM3JyQjlEVzE1RFZ6dG4zVS1KU0JkWDBiWTczNXZkVVNIZFdhNWRmRjVfNzZLZnlDcFEtMTNaX3FYaFZiQjk5QWo2UEJyYmYxSDZDcHFTemh6dVVXNA?oc=5","date":"2025-06-18","type":"regulatory","source":"Pharmaceutical Technology","summary":"Tisento’s MELAS treatment receives fast track status from FDA - Pharmaceutical Technology","headline":"Tisento’s MELAS treatment receives fast track status from FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNanhyaVhmanFEcEZmeFlHNm9qS3R1SFZFTDNYa2NEOXJsVHVSVTBrd1dBZUhHSUZEeExDWXM0T2thbFhIbXlfY2VuNDBXaWlTNUhkRkxCaEc5Q0RoRTFlLTVkQWZMODBlZHJlbU1KVERXN1JfYXR3d0Z3N3otbVZMd1BneTBYQmxrY0VGNzdhMGdwUGlubXh3U2RVeWVFLXJmUnhXbDdLbFVwSFNNNVNhWXJpeGJJZjljSVRFZ3dCVl8ybnNHb21ZOGUydVFZZ1MyRFRxLXVxOHRacE9odEJjQTNreGNXQmJjeDRuWg?oc=5","date":"2025-02-05","type":"pipeline","source":"BioSpace","summary":"Melas Syndrome Market Size to Reach USD 494.2 Million by 2035, Impelled by Increasing Prevalence of Genetic Mutations - BioSpace","headline":"Melas Syndrome Market Size to Reach USD 494.2 Million by 2035, Impelled by Increasing Prevalence of Genetic Mutations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5WRFhiT3pGc2VMWEJoTXhRc0Z2U3lpR29CU1RZSEdMTjY3RjRQazRQYklHY3QzbnJ2Qk8zSVlfakNXNDVkTXNPZFp1SGVuTXROcjZ1Z2ZRbkRtbXN5bkl2eVBlbGxrQmlsTU4xQ2ZhMldDSnd6ZDNQeWtDS0Y?oc=5","date":"2025-01-27","type":"trial","source":"Clinical Trials Arena","summary":"Tisento doses first subject in Phase IIb study of zagociguat for MELAS treatment - Clinical Trials Arena","headline":"Tisento doses first subject in Phase IIb study of zagociguat for MELAS treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQQTI0ZnNPUWZ3LUZNWDRlNEFRSWhaQV9hQXNPSTRhQjRuSjltc1lsQTltLUJydkQ5WkNJR3RrcGd4dWZwck1pa2lxekJxTmpoTjN6dU50Wkp6TkI4TGljamI5ZWtBUUVzNFd1UC1qa2Z4WWgwYi13MHk1Znd5TnY5TGh3UHBwemFJTS14X2Fnbw?oc=5","date":"2024-10-31","type":"pipeline","source":"Life Science Leader","summary":"Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader","headline":"Where Are They Now? Ironwood Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNdXZYSVNTX0szU2JkX293X21iYmw3cHdZWFpOMEJZX25CS215T2N2Q24wOTVoaEd5enplNkN6QTVvWWtFYS1LUnVBV1QxVHFYNkVydkxHaEtCazIyZVlwRGQteDNsazcwbEZSQXh5bG81a0FaU0pNV1hUdUdnMjJkag?oc=5","date":"2023-12-20","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQQzRsLVdfQjRaejktVEFRUGFMUHpHamcwMkVuRHl6RnhJTXNza3BpUG1Tck9wOW9qQ2lqSllRY1hNY21HbGNGTG5zWEZTaTBWOTZiSWxucGc1bDlQTE8wbmpETDJzdWw3QTIxc3VJVTQ3Vm50aFFDZEFUUWZCU0F1bVFwNmZfWUQ3QWlwQWpuOFdWeUJTWUo5YkJvQ1NQanRNa3pzV2FiNFFiZE11c1gxdllWZw?oc=5","date":"2023-07-31","type":"pipeline","source":"MedCity News","summary":"Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News","headline":"Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}